Share on StockTwits

Agenus (NASDAQ:AGEN) issued its quarterly earnings data on Thursday. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.12, Analyst RN reports. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.55 million.

Shares of Agenus (NASDAQ:AGEN) traded down 1.11% on Thursday, hitting $2.68. The stock had a trading volume of 77,127 shares. Agenus has a 1-year low of $2.27 and a 1-year high of $5.27. The stock has a 50-day moving average of $2.95 and a 200-day moving average of $3.04. The company’s market cap is $166.6 million.

AGEN has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Agenus from a “neutral” rating to an “outperform” rating in a research note on Monday, April 21st. They now have a $3.00 price target on the stock. On the ratings front, analysts at Maxim Group reiterated a “buy” rating on shares of Agenus in a research note on Monday, March 24th. Finally, analysts at MLV & Co
raised their price target on shares of Agenus from $9.00 to $11.00 in a research note on Friday, March 14th. They now have a “buy” rating on the stock.

Agenus Inc, including its subsidiaries, (NASDAQ:AGEN) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.